The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference
ConclusionsOur study demonstrated that BRAF status makes the difference in treatment ’s outcome. Therefore, the anti-EGFR should not be excluded in all advanced RCC but considered on a case-by-case basis.
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Colon Cancer | Colorectal Cancer | Gastroenterology | Italy Health | Peritoneal Cancer | Statistics | Study | Undifferentiated Carcinoma